Gertjan Rasschaert: Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Gertjan Rasschaert, Medical Doctor and Consultant specializing in Gastrointestinal Oncology and Gastroenterology at UZ Leuven, shared a post on LinkedIn:
“Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
A. Audisio et al.
International real-world study
61 centers, including UZ Leuven
21 countries
1585 patients treated off trial with TNT for stage II/III rectal adenocarcinoma
From 09/2012 to 12/2023
Outcome:
Primary: type of TNT
Secondary:
- patient characteristics
- treatment adherence
- safety
- efficacy overall and by type
Regimen:
🇫🇷 PRODIGE 23–like: 17.7%
🇳🇱 RAPIDO-like: 33.4%
🇺🇸 OPRA induction-like: 12.0%
🇺🇸 OPRA consolidation-like: 16.2%
🇺🇳 Other: 22.7%
After TNT:
Watch and wait: 12.1%
Local excision: 1.9%
pCR or cCR: 23.2%
Treatment failure:
Local: 8.5%
Distant: 16.4%
Endpoints:
3y-EFS: 68%
5y-OS: 79%
Conclusions:
– Substantial variation in choice of the TNT regimen
– Overall aligned with those reported in clinical trials
– Suggesting the efficacy of TNT in a clinical setting regardless of the specific regimen.
– Here, no differences in survival outcomes observed between TNT regimens.
‘Leuven Rectal Cancer Group’
Andre D’hoore, Albert Wolthuis, Gabriele Bislenghi, Lynn D., Elleke Dresen, Karin Haustermans, Xavier Sagaert (MD, PhD), Gert De Hertogh, Philippe Leclercq, Eric Van Cutsem, Jeroen Dekervel, Gertjan Rasschaert, Sabine Tejpar, Filip Van Herpe
Thanks to: Francesco Sclafani and Allesandro Audisio.”
Title: Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Authors: Alessandro Audisio, Chiara Gallio, Vaneja Velenik, Hélène Meillat, Erika Ruiz-Garcia, Maria Carmen Riesco, Javier Suárez Alecha, Gertjan Rasschaert, Carlos Carvalho, Violaine Randrian, Iva Kirac, Jorge Hernando, Mehmet Artaç, Juan Manuel O’Connor, Ithai Waldhorn, Pètra M. Braam, Ali Shamseddine, Roberto Moretto, Carolina De la Pinta, Francesca De Felice, Audrius Dulskas, David Páez López-Bravo, Alexander Vanden Bulcke, Felix Bock, Amélie Deleporte, Marc Van Den Eynde, Karen P. Geboes, Mauro Loi, Marco Messina, Constance Houlzé-Laroye, Alberto Puccini, Alessandro Pastorino, Demetris Papamichael, Michele Fiore, Daniel Sur, Michal Eid, Claire Antoun, Massimiliano Salati, Ingrid Garajovà, Matas Jakubauskas, Jiří Tomášek, Cidália Maria Sousa Pinto, Jerome Schwingel, Federica Morano, Richard A. Adams, Alexandre Dermine, Amélie Chau, Muhammad Ahsan Javed, Michele Ghidini, Francesco Fiorica, Paola Montenegro, Angelica Petrillo, Gaya Spolverato, Núria Mulet Margalef, Marie Diaz, Chiara Baratelli, Francesco Puleo, Athanasios Karampeazis, Fatma Sert, Quentin Gilliaux, Alfonso De Stefano, Gabriel Liberale, Luigi Moretti, Philippe Martinive, Vaiva Deltuvaite Thomas, Vincent Staggs, Everardo D. Saad, Jean-Luc Van Laethem, Francesco Sclafani
Read the Full Article on JAMA Oncology.
More posts featuring Gertjan Rasschaert.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023